scholarly journals Percutaneous cryoablation of a solitary, soft-tissue metastasis from renal cell carcinoma: a new local minimal invasive curative treatment

2019 ◽  
Vol 12 (3) ◽  
pp. e227129
Author(s):  
Theresa Junker ◽  
Benjamin Schnack Rasmussen ◽  
Anja Toft ◽  
Ole Graumann
Keyword(s):  
Renal Cell Carcinoma ◽  
Soft Tissue ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Late Onset ◽  
Outpatient Setting ◽  
Minimal Invasive ◽  
Soft Tissue Metastasis ◽  
Daily Routines

Cryoablation is a well-established treatment option, proven to be successful in treating local renal cell carcinoma (RCC). We treated a 67-year-old man in an outpatient setting with late onset of a 25 mm solitary soft-tissue metastasis of from RCC with cryoablation. The treatment was performed under sedation and in local anaesthesia. There were no complications during the procedure. The patient did not experience any adverse effects to the treatment. He was able to resume his normal daily routines the day after his treatment. A follow-up CT scan at 3, 8 and 12 months after treatment reported sufficient cryoablation and no sign of recurrence or other metastases.

Ischiogluteal bursitis mimicking soft-tissue metastasis from a renal cell carcinoma

1998 ◽  
Vol 8 (7) ◽  
pp. 1140-1141 ◽  
Author(s):  
M. Völk ◽  
J. Gmeinwieser ◽  
H. Hanika ◽  
C. Manke ◽  
M. Strotzer
Keyword(s):  
Renal Cell Carcinoma ◽  
Soft Tissue ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Soft Tissue Metastasis

Solitary sacral soft tissue metastasis from renal cell carcinoma

1998 ◽  
Vol 30 (1) ◽  
pp. 9-13 ◽  
Author(s):  
Z. Sinik ◽  
H. Biri ◽  
Ö. Ataoĝlu ◽  
B. Çelik ◽  
K. Karaca ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Soft Tissue ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Soft Tissue Metastasis

Soft tissue metastasis from a renal cell carcinoma

1994 ◽  
Vol 74 (6) ◽  
pp. 799-801 ◽  
Author(s):  
P. S. SIDHU ◽  
M. LEWIS ◽  
D. A. NICHOLSON
Keyword(s):  
Renal Cell Carcinoma ◽  
Soft Tissue ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Soft Tissue Metastasis

506: A Risk-Adjusted Follow-up for Patients with Stage I and II Renal Cell Carcinoma

2007 ◽  
Vol 177 (4S) ◽  
pp. 169-169
Author(s):  
Quoc-Dien Trinh ◽  
Pierre I. Karakiewicz ◽  
Thierry Lebeau ◽  
Dan Lewinshtein ◽  
Elie Antebi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Stage I

Comparing the Responses of Osseous Versus Soft-Tissue Metastases of Renal Cell Carcinoma to Receptor Tyrosine Kinase Inhibitors and Immunotherapy

Kidney Cancer ◽  
2020 ◽  
Vol 4 (3) ◽  
pp. 151-158
Author(s):  
Katherine Yuxi Tai ◽  
Jad M. El Abiad ◽  
Carol D. Morris ◽  
Mark Christopher Markowski ◽  
Adam S. Levin
Keyword(s):  
Renal Cell Carcinoma ◽  
Soft Tissue ◽  
Cell Carcinoma ◽  
Receptor Tyrosine Kinase ◽  
Renal Cell ◽  
Kinase Inhibitors ◽  
Tissue Response ◽  
Bone Response ◽  
Soft Tissue Response ◽  
Receptor Tyrosine Kinase Inhibitors

BACKGROUND: Checkpoint inhibitors and receptor tyrosine kinase inhibitors (RTKIs) have changed the standard of care for metastatic renal cell carcinoma (mRCC). Anecdotal evidence suggests these therapies may be less effective for treating bone than soft-tissue metastases. PURPOSE: We performed a retrospective review evaluating the relative clinical responses in soft-tissue and bone metastases in patients undergoing therapy using RTKIs and anti-programmed death-1 (PD-1) agents for mRCC. METHODS: Of the 2,212 patients in our institutional cancer registry with renal cell carcinoma (1997–2017), 68 (82 disease courses) were identified with measurable bone and soft-tissue metastases treated with RTKIs and/or PD-1s. Extent of metastasis was quantified at the time of therapy initiation (baseline) and at 3 months, 6 months, and 1 year. Changes in disease status were categorized as complete response, partial response, stable, mixed, or progression of disease according to RECIST v1.1 and MD Anderson criteria. These categories were further organized into “response to treatment” or “evidence of progression” to generate a generalized linear effects model with soft-tissue response as the independent variable and bone response as the dependent variable. Alpha = 0.05. RESULTS: Soft-tissue response correlated with bone response at 3 months (76 disease courses, p = 0.005) and 6 months (48 disease courses, p = 0.017). Of the patients with controlled soft-tissue disease, only 14 (19%) and 15 (32%) had progression in bone at 3 and 6 months, respectively. CONCLUSION: Contrary to anecdotal reports, osseous metastases do not appear to respond worse than soft-tissue metastases to treatment with these agents.

scholarly journals Identification of miR-20a-5p as Robust Normalizer for Urine microRNA Studies in Renal Cell Carcinoma and A Profile of Dysregulated microRNAs

2021 ◽  
Vol 22 (15) ◽  
pp. 7913
Author(s):  
Julia Oto ◽  
Raquel Herranz ◽  
Emma Plana ◽  
José Vicente Sánchez-González ◽  
Javier Pérez-Ardavín ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Diagnostic Value ◽  
Diagnostic Model ◽  
Low Grade ◽  
Non Invasive ◽  
Good Expression ◽  
Independent Cohort

Renal cell carcinoma (RCC) is the third most frequent urinary malignancy and one of the most lethal. Current diagnostic and follow-up techniques are harmful and unspecific in low-grade tumors. Novel minimally invasive markers such as urine microRNAs (miRNAs) are under study. However, discrepancies arise among studies in part due to lack of consent regarding normalization. We aimed to identify the best miRNA normalizer for RCC studies performed in urine samples together with a miRNA profile with diagnostic value and another for follow-up. We evaluated the performance of 120 candidate miRNAs in the urine of 16 RCC patients and 16 healthy controls by RT-qPCR followed by a stability analysis with RefFinder. In this screening stage, miR-20a-5p arose as the most stably expressed miRNA in RCC and controls, with a good expression level. Its stability was validated in an independent cohort of 51 RCC patients and 32 controls. Using miR-20a-5p as normalizer, we adjusted and validated a diagnostic model for RCC with three miRNAs (miR-200a-3p, miR-34a-5p and miR-365a-3p) (AUC = 0.65; Confidence Interval 95% [0.51, 0.79], p = 0.043). let-7d-5p and miR-205-5p were also upregulated in patients compared to controls. Comparing RCC samples before surgery and fourteen weeks after, we identified let-7d-5p, miR-152-3p, miR-30c-5p, miR-362-3p and miR-30e-3p as potential follow-up profile for RCC. We identified validated targets of most miRNAs in the renal cell carcinoma pathway. This is the first study that identifies a robust normalizer for urine RCC miRNA studies, miR-20a-5p, which may allow the comparison of future studies among laboratories. Once confirmed in a larger independent cohort, the miRNAs profiles identified may improve the non-invasive diagnosis and follow-up of RCC.

Imaging in the Follow-Up of Renal Cell Carcinoma

2012 ◽  
Vol 198 (6) ◽  
pp. 1266-1276 ◽  
Author(s):  
Uday Patel ◽  
Heminder Sokhi
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell
Sign in / Sign up

Export Citation Format

Share Document